8
ALL8
Sage TherapeuticsYear
8
ALL3
20242
20232
20221
2021DEALS // DEV.
8
ALL8
DevelopmentsCountry
8
ALL8
U.S.A8
ALL8
Not ApplicableTherapeutic Area
8
ALL3
Genetic Disease3
Neurology2
TechnologyStudy Phase
8
ALL2
Approved3
Phase III3
Phase IIDeal Type
0
ALLProduct Type
8
ALL8
Small moleculeDosage Form
6
ALL2
Capsule1
Oral Solution1
Soft gel Capsule2
TabletLead Product
8
ALL8
SAGE-718Target
3
ALL3
NMDA receptorSage Announces Phase 2 DIMENSION Study Results of Dalzanemdor in Huntington’s Disease
Details : SAGE-718 (dalzanemdor) is an oral, first-in-class investigational NMDA receptor positive allosteric modulator. It is being evaluated for treatment of mild cognitive impairment in hunginton’s disease.
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2024
Sage Therapeutics Scraps Alzheimer’s Drug Development After Trial Fails
Details : SAGE-718 (dalzanemdor) is an oral, first-in-class investigational NMDA receptor positive allosteric modulator. It is being evaluated for treatment of mild cognitive impairment in parkinson’s disease.
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 08, 2024
Sage Announces Topline Results from Phase 2 of Dalzanemdor
Details : SAGE-718 (dalzanemdor) is an oral, first-in-class investigational NMDA receptor positive allosteric modulator. It is being evaluated for mild cognitive impairment in parkinson’s disease.
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 17, 2024
Lead Product(s) : SAGE-718
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SAGE-718 is first-in-class NMDA receptor positive allosteric modulator and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including HD, PD...
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 18, 2023
Lead Product(s) : SAGE-718
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SAGE-718
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SAGE-718 is first-in-class NMDA receptor positive allosteric modulator and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including HD, PD...
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 22, 2023
Lead Product(s) : SAGE-718
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Phase 2 LUMINARY Study showed SAGE-718, a positive allosteric modulator of NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with MCI and dementia du...
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2022
Details : The PARADIGM Study is a Phase 2, open-label study evaluating the safety, tolerability, and efficacy of SAGE-718, first-in-class NMDA receptor PAM once daily in individuals with mild cognitive impairment due to Parkinson’s disease.
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2022
Lead Product(s) : SAGE-718
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SAGE-718, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease (HD), Parkinson’s disease (PD) and Alzheimer’s disease (AD).
Brand Name : SAGE-718
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 15, 2021
Lead Product(s) : SAGE-718
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?